Milestone Pharmaceuticals Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
MIST$0.66-10.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows** (Unaudited)**
(in thousands of US dollars)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Nine months ended September 30, | ||||||
| | | 2025 | 2024 | |||
| Cash flows used in operating activities | | | | | | |
| Net loss | | $(45,649) | | $(29,156) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | |
| Depreciation of property and equipment | | | 80 | | | 79 |
| Amortization of debt costs | | | 317 | | | 273 |
| Accretion of investment discount | | | (81) | | | (337) |
| Non-cash interest expense related to debt | | | 2,537 | | | 2,389 |
| Share-based compensation expense | | | 3,909 | | | 4,302 |
| Loss on disposals of property and equipment | | | — | | | 8 |
| Changes in operating assets and liabilities: | | | | | | |
| Other receivables | | | 790 | | | 1,997 |
| Research and development tax credits receivable | | | 93 | | | (194) |
| Prepaid expenses | | | (737) | | | 655 |
| Operating lease assets and liabilities | | | (11) | | | (17) |
| Accounts payable and accrued liabilities | | | 2,486 | | | (2,004) |
| | | | | | | |
| Net cash used in operating activities | | | (36,266) | | | (22,005) |
| | | | | | | |
| Cash provided by (used in) investing activities | | | | | | |
| Acquisition of property and equipment | | | (19) | | | (11) |
| Acquisition of short-term investments | | | (35,904) | | | (99,585) |
| Redemption of short-term investments | | | 44,466 | | | 88,545 |
| | | | | | | |
| Net cash provided by (used in) investing activities | | | 8,543 | | | (11,051) |
| | | | | | | |
| Cash provided by financing activities | | | | | | |
| Proceeds from exercise of options | | | 158 | | | 29 |
| Proceeds from issuance of common shares, net of issuance costs | | | 23,143 | | | 27,258 |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | | | 2,573 | | | 4,617 |
| Proceeds from issuance of series A common stock warrants, net of issuance costs | | | 9,504 | | | — |
| Proceeds from issuance of series B common stock warrants, net of issuance costs | | | 13,416 | | | — |
| Proceeds from employee stock purchase plan | | | 300 | | | 191 |
| | | | | | | |
| Cash provided by financing activities | | | 49,094 | | | 32,095 |
| | | | | | | |
| Net increase (decrease) in cash and cash equivalents | | | 21,371 | | | (961) |
| | | | | | | |
| Cash and cash equivalents – Beginning of period | | | 25,314 | | | 13,760 |
| | | | | | | |
| Cash and cash equivalents – End of period | | $46,685 | | $12,799 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.